Among KIT inhibitors, cabozantinib, exhibits notable clinical anti-tumor efficacy against GBM, in contrast to imatinib, tandutinib, and dasatinib, which have lower mean lipid solubilities, higher mean SAs, and comparable IC50 (mean 3.9 vs. 5.4, mean 104 vs. 98 Å2 and mean 34 vs. 1.8 μmoL/L respectively) (33–42). The gene discussed is KIT; the disease is neoplasm.